Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 1.736
5-Year Impact Factor – 2.135
Index Copernicus  – 168.52
MEiN – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

Ahead of print

doi: 10.17219/acem/157241

Publication type: meta-analysis

Language: English

License: Creative Commons Attribution 3.0 Unported (CC BY 3.0)

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Cite as:


Li T, Zou X, Kang Y, Sun M, Huang X, Duan X. A meta-analysis of the effect of multidisciplinary comprehensive care on health-related quality of life and Unified Parkinson’s Disease Rating Scale in Parkinson’s disease [published online as ahead of print on March 15, 2023]. Adv Clin Exp Med. 2023. doi:10.17219/acem/157241

A meta-analysis of the effect of multidisciplinary comprehensive care on health-related quality of life and Unified Parkinson’s Disease Rating Scale in Parkinson’s disease

Ting Li1,B,C, Xiumei Zou2,C,D, Yujuan Kang3,B,D,E, Mingzhu Sun1,B,C, Xi Huang1,B,C, Xiaoyan Duan4,A,E,F

1 School of Nursing, Shaanxi University of Chinese Medicine, Xianyang, China

2 Emergency Department,The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou, China

3 Nursing Department, Affiliated Hospital of Shaanxi University of Chinese Medicine, Xianyang, China

4 Outpatient Department, Affiliated Hospital of Shaanxi University of Chinese Medicine, Xianyang, China

Abstract

Introduction. According to many reports, multidisciplinary comprehensive care alleviates Parkinson’s disease (PD) more frequently than any other standard care, though the results were found to vary greatly.
Material and methods. A systematic literature search up to July 2022 was performed and 1234 related studies were evaluated. The chosen studies comprised 1115 subjects with PD who participated in baseline trials; 633 of them were under multidisciplinary comprehensive care, while 482 were under standard care. Odds ratios (ORs) and mean differences (MDs) with 95% confidence intervals (95% CIs) were calculated to measure the results of multidisciplinary comprehensive care for PD by the contentious and dichotomous approaches with a random or fixed influence model employed.
Results. The use of multidisciplinary comprehensive care resulted in significantly better health-related quality of life (HRQL) (MD: −3.17; 95% CI: −5.98–−0.35, p = 0.03) and Unified Parkinson’s Disease Rating Scale (UPDRS) score (MD: −5.25; 95% CI: −10.14–−0.37, p = 0.04) compared to the standard care for subjects with PD. Nevertheless, no significant difference was found between multidisciplinary comprehensive care and standard care for subjects with PD regarding medication dosage (MD: 0.31; 95% CI: −0.72–1.34, p = 0.56) and caregiver strain (MD: −0.51; 95% CI: −1.69–0.67, p = 0.40).
Conclusion. Outpatient multidisciplinary comprehensive care models may improve patient-reported HRQL and UPDRS score; nevertheless, no significant difference was found in terms of medication dosage and caregiver strain compared to the standard care for subjects with PD. The small sample size of 2 out of 7 analyzed studies and the small number of studies in certain comparisons requires attention when analyzing the results.

Key words

Parkinson’s disease, integrated care, health-related quality of life, Unified Parkinson’s Disease Rating Scale

Graphical abstract


Graphical abstracts

References (67)

  1. Litvan I. What is the accuracy of the clinical diagnosis of multiple system atrophy? A clinicopathologic study. Arch Neurol. 1997;54(8):937–944. doi:10.1001/archneur.1997.00550200007003
  2. Espay AJ. What the VaP? The meaning of “vascular parkinsonism.” Parkinsonism Relat Disord. 2022;94:132–134. doi:10.1016/j.parkreldis.2021.12.008
  3. Caproni S, Colosimo C. Diagnosis and differential diagnosis of Parkinson disease. Clinics Geriatr Med. 2020;36(1):13–24. doi:10.1016/j.cger.2019.09.014
  4. Zijlmans JCM, Daniel SE, Hughes AJ, Révész T, Lees AJ. Clinicopathological investigation of vascular parkinsonism, including clinical criteria for diagnosis. Mov Disord. 2004;19(6):630–640. doi:10.1002/mds.20083
  5. Liaqat H, Parveen A, Kim SY. Neuroprotective natural products’ regulatory effects on depression via gut–brain axis targeting tryptophan. Nutrients. 2022;14(16):3270. doi:10.3390/nu14163270
  6. Wang Z, Pi YL, Wu Y, et al. Selective effects of exercise on reactive and proactive inhibition in Parkinson’s disease. PeerJ. 2022;10:e13628. doi:10.7717/peerj.13628
  7. Wang C, Chen L, Zhang M, Yang Y, Wong G. PDmethDB: A curated Parkinson’s disease associated methylation information database. Comput Struct Biotechnol J. 2020;18:3745–3749. doi:10.1016/j.csbj.2020.11.015
  8. Török N, Maszlag-Török R, Molnár K, et al. Single nucleotide polymorphisms of indoleamine 2,3-dioxygenase 1 influenced the age onset of Parkinson’s disease. Front Biosci (Landmark Ed). 2022;27(9):265. doi:10.31083/j.fbl2709265
  9. Holland C, Garner I, Simpson J, et al. Impacts of COVID-19 lockdowns on frailty and wellbeing in older people and those living with long-term conditions. Adv Clin Exp Med. 2021;30(11):1111–1114. doi:10.17219/acem/144135
  10. Tanaka M, Szabó Á, Spekker E, Polyák H, Tóth F, Vécsei L. Mitochondrial impairment: A common motif in neuropsychiatric presentation? The link to the tryptophan–kynurenine metabolic system. Cells. 2022;11(16):2607. doi:10.3390/cells11162607
  11. Tanaka M, Toldi J, Vécsei L. Exploring the etiological links behind neurodegenerative diseases: Inflammatory cytokines and bioactive kynurenines. Int J Mol Sci. 2020;21(7):2431. doi:10.3390/ijms21072431
  12. Zhang YJ, Zhu WK, Qi FY, Che FY. CircHIPK3 promotes neuroinflammation through regulation of the miR-124-3p/STAT3/NLRP3 signaling pathway in Parkinson’s disease [published online ahead of print on October 28, 2022]. Adv Clin Exp Med. 2022. doi:10.17219/acem/154658
  13. Sini P, Dang TBC, Fais M, et al. Cyanobacteria, cyanotoxins, and neurodegenerative diseases: Dangerous liaisons. Int J Mol Sci. 2021;22(16):8726. doi:10.3390/ijms22168726
  14. Tanaka M, Spekker E, Szabó Á, Polyák H, Vécsei L. Modelling the neurodevelopmental pathogenesis in neuropsychiatric disorders: Bioactive kynurenines and their analogues as neuroprotective agents. In celebration of 80th birthday of Professor Peter Riederer. J Neural Transm. 2022;129(5–6):627–642. doi:10.1007/s00702-022-02513-5
  15. Nyatega CO, Qiang L, Adamu MJ, Kawuwa HB. Gray matter, white matter and cerebrospinal fluid abnormalities in Parkinson’s disease: A voxel-based morphometry study. Front Psychiatry. 2022;13:1027907. doi:10.3389/fpsyt.2022.1027907
  16. Battaglia S. Neurobiological advances of learned fear in humans. Adv Clin Exp Med. 2022;31(3):217–221. doi:10.17219/acem/146756
  17. Carrera-González M del P, Cantón-Habas V, Rich-Ruiz M. Aging, depression and dementia: The inflammatory process. Adv Clin Exp Med. 2022;31(5):469–473. doi:10.17219/acem/149897
  18. Hsu YL, Hung HS, Tsai CW, et al. Peiminine reduces ARTS-mediated degradation of XIAP by modulating the PINK1/parkin pathway to ameliorate 6-hydroxydopamine toxicity and α-synuclein accumulation in Parkinson’s disease models in vivo and in vitro. Int J Mol Sci. 2021;22(19):10240. doi:10.3390/ijms221910240
  19. Tanaka M, Vécsei L. Editorial of Special Issue ‘Dissecting Neurological and Neuropsychiatric Diseases: Neurodegeneration and Neuroprotection.’ Int J Mol Sci. 2022;23(13):6991. doi:10.3390/ijms23136991
  20. Török N, Tanaka M, Vécsei L. Searching for peripheral biomarkers in neurodegenerative diseases: The tryptophan–kynurenine metabolic pathway. Int J Mol Sci. 2020;21(24):9338. doi:10.3390/ijms21249338
  21. Chen C. Recent advances in the study of the comorbidity of depressive and anxiety disorders. Adv Clin Exp Med. 2022;31(4):355–358. doi:10.17219/acem/147441
  22. Cao X, Yang F, Zheng J, Wang X, Huang Q. Aberrant structure MRI in Parkinson’s disease and comorbidity with depression based on multinomial tensor regression analysis. J Pers Med. 2022;12(1):89. doi:10.3390/jpm12010089
  23. Mazzoni P, Shabbott B, Cortes JC. Motor control abnormalities in Parkinson’s disease. Cold Spring Harb Perspect Med. 2012;2(6):a009282. doi:10.1101/cshperspect.a009282
  24. Battaglia S, Cardellicchio P, Di Fazio C, Nazzi C, Fracasso A, Borgomaneri S. Stopping in (e)motion: Reactive action inhibition when facing valence-independent emotional stimuli. Front Behav Neurosci. 2022;16:998714. doi:10.3389/fnbeh.2022.998714
  25. Chung EJ, Cho HJ, Hur DY, Kim YS, Lee KH, Kim SJ. One autopsy proved neocortical Lewy body disease without the involvement of the olfactory bulb and brainstem. J Korean Med Sci. 2022;37(23):e195. doi:10.3346/jkms.2022.37.e195
  26. Lee SH, Kim M, Lee J, et al. Clinical factors and dopamine transporter availability for the prediction of outcomes after globus pallidus deep brain stimulation in Parkinson’s disease. Sci Rep. 2022;12(1):16870. doi:10.1038/s41598-022-19150-3
  27. Dickson DW. Neuropathology of Parkinson disease. Parkinsonism Relat Disord. 2018;46(Suppl 1):S30–S33. doi:10.1016/j.parkreldis.2017.07.033
  28. Karni L, Jusufi I, Nyholm D, Klein GO, Memedi M. Toward improved treatment and empowerment of individuals with Parkinson disease: Design and evaluation of an Internet of things system. JMIR Form Res. 2022;6(6):e31485. doi:10.2196/31485
  29. Riggare S, Stamford J, Hägglund M. A long way to go: Patient perspectives on digital health for Parkinson’s disease. J Parkinsons Dis. 2021;11(Suppl 1):S5–S10. doi:10.3233/JPD-202408
  30. Dunn D, Williams A, Giust J, Kronenberger W. Epilepsy and attention-deficit hyperactivity disorder: Links, risks, and challenges. Neuropsychiatr Dis Treat. 2016;12:287–296. doi:10.2147/NDT.S81549
  31. Simonet C, Noyce AJ. Domotics, smart homes, and Parkinson’s disease. J Parkinsons Dis. 2021;11(Suppl 1):S55–S63. doi:10.3233/JPD-202398
  32. Spreadbury JH, Young A, Kipps CM. A comprehensive literature search of digital health technology use in neurological conditions: Review of digital tools to promote self-management and support. J Med Internet Res. 2022;24(7):e31929. doi:10.2196/31929
  33. Battaglia S, Cardellicchio P, Di Fazio C, Nazzi C, Fracasso A, Borgomaneri S. The influence of vicarious fear-learning in “infecting” reactive action inhibition. Front Behav Neurosci. 2022;16:946263. doi:10.3389/fnbeh.2022.946263
  34. Klucken J, Krüger R, Schmidt P, Bloem BR. Management of Parkinson’s disease 20 years from now: Towards digital health pathways. J Parkinsons Dis. 2018;8(Suppl 1):S85–S94. doi:10.3233/JPD-181519
  35. Bloem BR, Okun MS, Klein C. Parkinson’s disease. Lancet. 2021;397(10291):2284–2303. doi:10.1016/S0140-6736(21)00218-X
  36. Borgomaneri S, Serio G, Battaglia S. Please, don’t do it! Fifteen years of progress of non-invasive brain stimulation in action inhibition. Cortex. 2020;132:404–422. doi:10.1016/j.cortex.2020.09.002
  37. Mai T. Stand und Entwicklung der Rolle als Parkinson Nurse in Deutschland: Eine Online-Befragung. Pflege. 2018;31(4):181–189. doi:10.1024/1012-5302/a000617
  38. Vlaanderen FP, Rompen L, Munneke M, Stoffer M, Bloem BR, Faber MJ. The voice of the Parkinson customer. J Parkinsons Dis. 2019;9(1):197–201. doi:10.3233/JPD-181431
  39. Battaglia S, Fabius JH, Moravkova K, Fracasso A, Borgomaneri S. The neurobiological correlates of gaze perception in healthy individuals and neurologic patients. Biomedicines. 2022;10(3):627. doi:10.3390/biomedicines10030627
  40. Poewe W. Clinical measures of progression in Parkinson’s disease. Mov Disord. 2009;24(Suppl 2):S671–S676. doi:10.1002/mds.22600
  41. Ebersbach G, Baas H, Csoti I, Müngersdorf M, Deuschl G. Scales in Parkinson’s disease. J Neurol. 2006;253(Suppl 4):iv32–iv35. doi:10.1007/s00415-006-4008-0
  42. Stroup DF. Meta-analysis of observational studies in epidemiology: A proposal for reporting. JAMA. 2000;283(15):2008. doi:10.1001/jama.283.15.2008
  43. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. J Clin Epidemiol. 2009;62(10):e1–e34. doi:10.1016/j.jclinepi.2009.06.006
  44. Gupta A, Das A, Majumder K, et al. Obesity is independently associated with increased risk of hepatocellular cancer-related mortality: A systematic review and meta-analysis. Am J Clin Oncol. 2018;41(9):874–881. doi:10.1097/COC.0000000000000388
  45. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). Cochrane Collaboration, 2011. https://handbook-5-1.cochrane.org/.
  46. Sheikhbahaei S, Trahan TJ, Xiao J, et al. FDG-PET/CT and MRI for evaluation of pathologic response to neoadjuvant chemotherapy in patients with breast cancer: A meta-analysis of diagnostic accuracy studies. Oncologist. 2016;21(8):931–939. doi:10.1634/theoncologist.2015-0353
  47. Higgins JPT. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–560. doi:10.1136/bmj.327.7414.557
  48. Wade DT, Gage H, Owen C, Trend P, Grossmith C, Kaye J. Multidisciplinary rehabilitation for people with Parkinson’s disease: A randomised controlled study. J Neurol Neurosurg Psychiatry. 2003;74(2):158–162. doi:10.1136/jnnp.74.2.158
  49. Tickle-Degnen L, Ellis T, Saint-Hilaire MH, Thomas CA, Wagenaar RC. Self-management rehabilitation and health-related quality of life in Parkinson’s disease: A randomized controlled trial. Mov Disord. 2010;25(2):194–204. doi:10.1002/mds.22940
  50. van der Marck MA, Bloem BR, Borm GF, Overeem S, Munneke M, Guttman M. Effectiveness of multidisciplinary care for Parkinson’s disease: A randomized, controlled trial. Mov Disord. 2013;28(5):605–611. doi:10.1002/mds.25194
  51. Gage H, Grainger L, Ting S, et al. Specialist rehabilitation for people with Parkinson’s disease in the community: A randomised controlled trial. Health Serv Deliv Res. 2014;2(51):1–376. doi:10.3310/hsdr02510
  52. Eggers C, Dano R, Schill J, Fink GR, Hellmich M, Timmermann L; CPN study group. Patient-centered integrated healthcare improves quality of life in Parkinson’s disease patients: A randomized controlled trial. J Neurol. 2018;265(4):764–773. doi:10.1007/s00415-018-8761-7
  53. Lo Buono V, Palmeri R, De Salvo S, et al. Anxiety, depression, and quality of life in Parkinson’s disease: The implications of multidisciplinary treatment. Neural Regen Res. 2021;16(3):587–590. doi:10.4103/1673-5374.293151
  54. Mitsui T, Arii Y, Tsukamoto A, et al. Sociability‐based fitness approach in Parkinson’s disease: Comparison with conventional rehabilitation. Eur J Neurol. 2021;28(6):1893–1900. doi:10.1111/ene.14798
  55. Kruis AL, Smidt N, Assendelft WJ, et al. Integrated disease management interventions for patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2013;9(9):CD009437. doi:10.1002/14651858.CD009437.pub2
  56. Wang SM, Hsiao LC, Ting IW, et al. Multidisciplinary care in patients with chronic kidney disease: A systematic review and meta-analysis. Eur J Intern Med. 2015;26(8):640–645. doi:10.1016/j.ejim.2015.07.002
  57. Hoerger M, Wayser GR, Schwing G, Suzuki A, Perry LM. Impact of interdisciplinary outpatient specialty palliative care on survival and quality of life in adults with advanced cancer: A meta-analysis of randomized controlled trials. Ann Behav Med. 2019;53(7):674–685. doi:10.1093/abm/kay077
  58. Galbraith L, Jacobs C, Hemmelgarn BR, Donald M, Manns B, Jun M. Chronic disease management interventions for people with chronic kidney disease in primary care: A systematic review and meta-analysis. Nephrol Dial Transplant. 2017;33(1):112–121. doi:10.1093/ndt/gfw359
  59. Üstün TB, Kostanjesek N, Chatterji S, Rehm J, eds. Measuring Health and Disability: Manual for WHO Disability Assessment Schedule (WHODAS 2.0). Geneva, Switzerland: World Health Organization; 2010. https://apps.who.int/iris/handle/10665/43974. ISBN:978-92-4-154759-8.
  60. Valentijn PP, Vrijhoef HJM, Ruwaard D, Boesveld I, Arends RY, Bruijnzeels MA. Towards an international taxonomy of integrated primary care: A Delphi consensus approach. BMC Fam Pract. 2015;16(1):64. doi:10.1186/s12875-015-0278-x
  61. Valentijn PP, Pereira F, Sterner CW, et al. Validation of the Rainbow Model of Integrated Care Measurement Tools (RMIC-MTs) in renal care for patient and care providers. PLoS One. 2019;14(9):e0222593. doi:10.1371/journal.pone.0222593
  62. Stember M. Advancing the social sciences through the interdisciplinary enterprise. Soc Sci J. 1991;28(1):1–14. doi:10.1016/0362-3319(91)90040-B
  63. World Health Organization. Regional Office for Europe. Roadmap: Strengthening people-centred health systems in the WHO European Region. A framework for action towards Coordinated/Integrated Health Services Delivery (CIHSD). 2013. https://apps.who.int/iris/bitstream/handle/10665/108628/WHO-EURO-2013-4492-44255-62514-eng.pdf?sequence=1&isAllowed=y. Accessed March 1, 2022.
  64. Radder DLM, de Vries NM, Riksen NP, et al. Multidisciplinary care for people with Parkinson’s disease: The new kids on the block! Exp Rev Neurother. 2019;19(2):145–157. doi:10.1080/14737175.2019.1561285
  65. Marumoto K, Yokoyama K, Inoue T, et al. Inpatient enhanced multidisciplinary care effects on the quality of life for Parkinson disease: A quasi-randomized controlled trial. J Geriatr Psychiatry Neurol. 2019;32(4):186–194. doi:10.1177/0891988719841721
  66. Rajan R, Brennan L, Bloem BR, et al. Integrated care in Parkinson’s disease: A systematic review and meta-analysis. Mov Disord. 2020;35(9):1509–1531. doi:10.1002/mds.28097
  67. Seid AA, Demirdel E, Aychiluhm SB, Mohammed AA. Multidisciplinary rehabilitation for people with Parkinson’s disease: A systematic review and meta-analysis. Parkinson’s Dis. 2022;2022:2355781. doi:10.1155/2022/2355781
© Wroclaw Medical University